We examined the agonistic and antagonistic activities of three categories of pharmaceuticals, including selective estrogen receptor modulators (SERM), tamoxifen (Tam), raloxifene (Ral) and clomiphene citrate (CC); a``pure'' ER antagonist, ICI 182,780 (ICI); and a subtype (ERa)-selective agonist, propyl pyrazole triol (PPT), using our newly established reporter yeast strains (Saccharomyces cerevisiae), which express human ERa or ERb. These strains also contain a reporter plasmid carrying one copy of estrogen responsive element (ERE) upstream of the bgalactosidase gene, and a plasmid expressing a steroid receptor coactivator, SRC-1e. In the ERa assay, none of the tested pharmaceuticals demonstrated antagonistic activity, whereas all showed weak agonistic activity at concentrations higher than 1×10 -7 M. In the ERb assay, Tam, CC and ICI showed antagonistic activity, whereas only Ral showed agonistic activity at concentrations higher than 1×10 -8 M. The distinct estrogenic response in the ERa and ERb assays was mainly due to their diŠer-ences in ligand a‹nity and interaction with coactivators. PPT showed an agonistic eŠect in the ERa assay, but not in the ERb assay. This study showed that our ERa and ERb reporter yeasts have diŠerent responses to the test pharmaceuticals and are able to distinguish subtype-selective ligands. These reporter yeasts are applicable for exploring ER subtype-speciˆc therapeutic agents and for detecting leaked pharmaceuticals that may act as environmental endocrine disruptors.
Introduction
Estrogens play an important role in the control of growth, development, and metabolic homeostasis in various tissues. These eŠects are mediated by estrogen receptor (ER) (1) . ER is a ligand-activated transcription factor, and a member of the steroid/nuclear receptor superfamily. The malfunction of nuclear steroid and thyroid hormone receptors is related to various disorders, including cancers, cardiovascular diseases and metabolic disorders (1) .
Humans have two ER subtypes, ERa and ERb. Both ERs contain an activation domain 1 (AF1) at the N-terminus, a DNA binding domain (DBD) in the middle and a ligand binding domain (LBD) at the C-terminal. The DNA binding domain of the two ER subtypes is highly conserved (96z homology of amino acid), while amino acid homology of the ligand binding domain and of the overall coding region between two subtypes is about 59z and 47z, respectively (2) . The diŠerence in the structure of these 2 subtypes may aŠect the interaction with the ER response element (ERE), ligands and coactivators, resulting in diŠerent transcriptional activity; therefore, the responses of various ligands to both ER subtypes were investigated in this study.
Recently, we have reported our newly constructed yeast strains, which can respond to estrogenic ligands dose-dependently and are applicable to screen environmental endocrine disruptors (3) . The yeast strains express human ERa or ERb cDNA, and have an EREpromotive b-galactosidase reporter plasmid. Steroid receptor coactivator-1 (SRC-1) was co-expressed in our yeasts to increase the assay sensitivity as well as to investigate the eŠect of that coactivator on estrogenic activity in response to various chemicals. SRC-1 has been reported to enhance the transcriptional activity of ER remarkably in response to ligands (4) (5) (6) .
The main objective of the current study was to validate the estrogenic response of these yeast strains to pharmaceuticals, mainly SERMs and an ER antagonist. A mammalian assay is the most common assay to detect the estrogenic activity of pharmaceuticals designed for humans; however, in mammalian cells, some transcrip- tional factors, including coactivators and corepressors, are expressed at various levels in diŠerent cell types, and they interact with each other, resulting in cell-or tissuespeciˆc transcriptional responses (7) (8) . Intrinsic transcriptional factors interacting with human ERs are not supposed to be expressed in yeasts; therefore, the estrogenic activity demonstrated by yeast assay would give insights into the most direct signaling pathway of transcriptional factors acting on ERs. Additionally, compared with mammalian cell assays, yeast assays are more cost-eŠective, easier to handle and more consistent.
Three categories of pharmaceuticals were tested in the current study. Selective estrogen receptor modulators (SERM), including tamoxifen (Tam), raloxifene (Ral) and clomiphene citrate (CC); a``pure'' ER antagonist, ICI 182,780 (ICI); and a subtype (ERa) selective agonist, propyl pyrazole triol (PPT) (Fig. 1) were chosen mainly based on their widespread use and their three diŠerent categories. SERMs are deˆned as a class of medication that exhibits an agonistic eŠect on some tissues but acts as antagonist on others in response to ER (9) . In contrast, a full agonist is deˆned as a chemical that has agonistic activity in all tissues, whereas a pure antagonist is a chemical which exerts antagonistic eŠects on all tissues (9) . These drugs are widely used to treat ER-associated diseases and in hormone therapy.
Materials and Methods
Pharmaceuticals: General chemicals, essentially analytical grade, were purchased from Nacalai Tesque (Kyoto, Japan), Sigma-Aldrich Japan (Tokyo, Japan) or Tokyo Chemical Industries (Japan). The pharmaceuticals used in this study and their suppliers are as follows: CC and Tam, Sigma-Aldrich Japan (Tokyo, Japan); Ral, LKT Laboratories (Minnesota, USA); PPT, Cayman Chemical Company (Michigan, USA); and ICI, Tocris Cookson Ltd (Bristol, UK).
ERa and ERb reporter yeasts: The reporter assay yeasts used in the current study for measuring ERa or ERb ligand activity were constructed and characterized by the authors (3). The yeasts contain an expression construct of either human ERa or ERb cDNA in their genome. Both ERa-and ERb-expressing yeasts carry an episomal SRC-1 expression plasmid and an episomal reporter plasmid which has one copy of ERE inserted upstream of CYC1 minimal promoter and b-galactosidase reporter gene. The third base just upstream of the start codon of ERa and ERb was assigned as adenine, and addition of the polyadenylation signal as a termination sequence were key modiˆcations for establishment of the assay yeasts in order to increase their sensitivities.
Estrogenic activity assay: The assays were conducted using a 96-well microtiter plate method (10) with minor modiˆcations. Both strains were precultured in selective growth medium containing 50 mM glucose (but without galactose). In ligand assays, the growth medium contained 50 mM glucose, 50 mM galactose, o-nitrophenyl-b-D-galactopyranoside (ONPG) and various concentrations of ligands. The following pharmaceuticals were used as ER ligands: 17b-estradiol (E2), Tam, Ral, CC, ICI and PPT. All ligands were dissolved in dimethylsulfoxide (DMSO). The concentration of DMSO in the assay medium was always maintained strictly at 1.0-1.1z in all assays. DMSO without any ligands was regarded as blank. The plates were incubated at 309 C, and absorbances at OD405 and OD595 of the medium were measured with a microplate reader (Model 680; BIO-RAD, Hercules, CA, U.S.A.) on the third day after incubation. OD405 and OD595 values represent b-galactosidase activity and cell density, respectively. Both values were measured in triplicate for each tested concentration in a single experiment, and all experiments were repeated independently at least 3 times. In each experiment, various concentrations of E2 were assayed to generate a standard curve for comparison.``Increase of induction'' was calculated by the following equation: s OD405(sample)÷OD595(sample)ts OD405(blank)÷OD595(blank)t . OD595 was measured everyday to check if any cytotoxicity appeared.
Results
Measurement of antagonistic activity of SERMs and ICI in ERa and ERb yeast assays: Estrogenic activities of mixtures of pharmaceuticals with various concentrations of E2 were measured in ERa (Fig. 2) and ERb yeast assays ( Fig. 3) with respect to SERMs, including Tam, CC and Ral and one pure antagonist, ICI.
In the ERa yeast assay, no pharmaceuticals showed antagonistic activity at any concentrations examined; however, various extents of agonistic activity were observed when mixing 1×10 -6 M of the pharmaceuticals with E2 at concentrations of 1×10 -12 M to 1×10 -9 M (Fig. 2) . The maximal activity of the mixture of pharmaceuticals and E2 remained the same as that of E2.
In the ERb yeast assay, among the tested pharmaceuticals, Tam, CC and ICI showed antagonistic activity at 1×10 -6 M (Fig. 3a, b, d) . When 1×10 -6 M Tam was added to E2, the EC50 was shifted from 3.50×10 -10 M to 2.97×10 -9 M, and maximal activity was decreased from 1.29 to 1.10, which was approximately 14z reduction (Fig. 3a) . Similarly, when 1×10 -6 M CC was added to E2, EC50 was shifted to 3.30×10 -9 M (Fig.  3b) . Furthermore, the pure anti-estrogen, ICI 182,780, showed weak antagonistic activity in the current study (Fig. 3d) , EC50 was shifted to 1.36×10 -9 M when 1× 10 -6 M ICI was added to E2. Another SERM, Ral, did not show any antagonistic activity; however, 1×10 -6 M of Ral exhibited some agonistic activity (Figs. 3c and  4b) . When 1×10 -6 M Ral was added to 1×10 -12 M E2, which is an ineŠective concentration, activity increased from 0.21 to 0.69, about a 3-fold increment.
Measurement of agonistic activity of SERMs and ICI in ERa and ERb assays: As the antagonistic assays (Figs. 2 and 3 ) apparently indicated that most pharmaceuticals are ER agonists at high concentration, agonistic activity was also measured by ERa and ERb assay yeasts (Fig. 4) .
In the ERa assay, all pharmaceuticals showed agonistic activity to various extents when the concentrations reached 1×10 -6 M (Fig. 4a) . Table 1 shows the EC50 values of the pharmaceuticals calculated from Fig. 4a . The ranking of the values was E2ºRalºTamºCCº ICI. The maximal activity of the pharmaceuticals relative to E2 (100z) is also shown in Table 1 . The ranking of the values was RalÀICIÀCCÀTam.
In the ERb assay, only Ral exhibited agonistic activity when its concentration was higher than 1×10 -8 M. Its EC50 value was 4.37×10 -7 M, 1,000 times less potent than E2, while its maximal activity was 75.2z of E2 (Table 1) . Other pharmaceuticals had no obvious agonistic activity in the ERb assay. These results are consistent with theˆndings shown in Figs. 2 and 3 .
Measurement of agonistic and antagonistic activity of an ERa-selective agonist PPT in ERa and ERb yeast assays: As PPT is known as an ERa-selective agonist in mammalian cells, its agonistic and antagonistic activities were examined in ERa and ERb yeast assays in the current study.
Agonistic activity of PPT was found in the ERa assay (Fig. 5a ), but not in the ERb assay (Fig. 5b) . The EC50 value of PPT was 4.86×10 -7 M, that is, about 1,000 times less potent than E2 (5.61×10 -10 ) in the ERa assay ( Table 1 ). The maximal activity of PPT was 1.97, while that of E2 was 2.85, that is, approximately 30z lower than that of E2 in the ERa assay.
Antagonistic activity of PPT was measured by mixing theˆxed concentrations of PPT (1×10 -6 M and 1× 10 -10 M) with various concentrations of E2. No antagonistic activity was observed in either ERa (Fig. 5c) or ERb (Fig. 5d) assays.
Discussion
SERMs have been reported to have cell-and tissuespeciˆc estrogenic eŠects in mammalian assays. In this present study, our previously constructed yeasts (3) were applied to investigate the agonistic and antagonistic eŠects of 5 pharmaceuticals, including three SERMs (Tam, CC and Ral), one``pure'' ER antagonist (ICI) and one ERa selective agonist (PPT).
In the ERa assay, none of the tested pharmaceuticals demonstrated antagonistic activity, whereas all showed weak agonistic activity at concentrations higher than 1 ×10 -7 M (Figs. 2 and 4) . EC50 values of these pharmaceuticals showed that they are about 1,000 times less potent than E2 (Table 1) . Tam was found to have agonistic activity in the YES assay (yeast without coactivator) (11, 12) , consistent with the current study.
In the ERb assay, Tam, CC and ICI showed antagonistic activity (Fig. 3) , whereas only Ral showed agonistic activity at concentrations higher than 1×10 -8 M (Figs. 3, 4b) . Tam, CC and ICI did not show any agonistic activity in the ERb assay, in contrast with the results of the ERa assay. A 3-dimenstional structure showed that interactions of Ral with ERa and ERb were similar (13), which could be one possible explanation why ERa and ERb had similar estrogenic response to Ral. On the other hand, diŠerent responses of Tam, CC and ICI (1×10 -6 M) in the ERa and ERb assay yeasts (Figs. 2 and 3 ) may be due to the diŠerent interaction of the complex consisting of a ligand (e.g., pharmaceutical), ER and SRC-1, but were unsolved systematically in the present study.
Since ERa and ERb have diŠerent biological functions (14) , the development of ER subtype-selective pharmaceuticals is increasingly important for clinical exploration. As propyl pyrazole triol (PPT) represents theˆrst ERa-selective agonist, its estrogenic response was examined in our yeast assays. PPT showed an agonistic eŠect in the ERa assay, but not in the ERb assay (Fig. 5) . No antagonistic activity was detected in either ERa or ERb assays, as expected. This result is consistent with the mammalian assay (15) . Structure analysis of the interaction of PPT with ERs indicated that PPT had higher binding a‹nity and potency selectively to ERa than to ERb due to their diŠerent binding pocket structure (16) . Theseˆndings explain the speciˆcity of ER subtypes in response to PPT in our yeast assays.
In mammalian cells, ERa and ERb caused distinct conformational change in response to ligands (13) and thus had diŠerent abilities to recruit coactivators (17, 18) . Interaction with coactivators and corepressors plays a critical role in agonistic and antagonistic eŠects. If ligand-bound ERs induced coactivator recruitment, the agonistic eŠect would be exhibited (19) . If the conformational change of ligand-bound ERs induced the recruitment of corepressors or blocking of coactivators, an antagonistic eŠect would be exerted (20) (21) (22) . The crystal structure of the ligand-bound ER hormone-binding domain (HBD) showed that both Tam and Ral exerted their antagonistic eŠect by competing with E2 binding and by blocking the interaction with coactivators (20, 22) . In contrast, their antagonistic eŠects were exerted if the conformational change of ERs induced the recruitment of corepressors (19, 21) . If the ligands can induce the binding of ERs to both coactivator and corepressor, the overall balance of the relative expression of coactivators and corepressors would become a critical determinant of their tissue-speciˆc action. For example, in the study of endometrial adenocarcinoma (Ishikawa) cells, Tam was found to induce the recruitment of coactivators, whereas it induced the recruitment of corepressors in breast cancer cells (21) . In such a case, the agonistic eŠect of Tam is exhibited when a coactivator, SRC-1, is highly expressed (21) . In the reporter yeasts (without coactivator) constructed by Routledge et al. (23) , Tam was reported to exhibit inhibitory eŠect when mixed with E2. One possible explanation for the diŠerent results in this study in comparison with other assays may be due to diŠerent status of coregulators (4) (5) (6) . Promoter context proved to be another determinant of tissue-speciˆc responses when hydroxy-Tam and Tam acted on ERs (21) . Similar binding a‹nities of ERa and ERb were observed when acting on AP-1 promoter element in mammalian cells (24) . Their results diŠered from that of the current study would be due to diŠerent promoter context used. Ligand-bound ER can bind to the promoter of a target gene indirectly through a mechanism involving other transcriptional factors, resulting in the exertion of a diŠerent estrogenic activity (21) . Since our yeasts did not express other human transcriptional factors, this possibility would be eliminated. The agonistic and antagonistic activities shown in the current study inevitably resulted from the interaction of a given ER subtype interacting with ERE (one copy).
This study showed that our ERa and reporter yeasts have diŠerent responses to the test pharmaceuticals and are able to distinguish subtype-selective ligands. The EC 50 of E2 in ERa and ERb assay are 5.61×10
-10 M and 3.50×10 -10 M, respectively, indicating its high sensitivity in response to ligands. These reporter yeasts are applicable for exploring ER subtype-speciˆc therapeutic agents and for detecting pharmaceuticals which are leaked to environment and may act as endocrine disruptors.
